Published on 11 Mar 2024 on Zacks via Yahoo Finance
Shares of Replimune Group, Inc. (REPL) have gained 16.4% over the past four weeks to close the last trading session at $9.03, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13.56 indicates a potential upside of 50.2%.
The mean estimate comprises nine short-term price targets with a standard deviation of $2.60. While the lowest estimate of $10 indicates a 10.7% increase from the current price level, the most optimistic analyst expects the stock to surge 110.4% to reach $19. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable.